Inspiremd congratulates crest-2 investigators on completion of trial enrollment

Cguard was the only investigational carotid stent approved by fda for inclusion in the trials crest-2 included 23 cases implanted with cguard tel aviv, israel and miami, aug. 05, 2024 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for the prevention of stroke, today congratulated the lead investigators on the completion of enrollment in the crest-2 (carotid revascularization endarterectomy or stenting trial) clinical trials. the cguard carotid stent, utilizing its proprietary micronet™ mesh, was included as a device option for stenting in the crest-2 trials following fda approval of inspiremd's investigational device exemption (ide) supplement application in february 2022.
NSPR Ratings Summary
NSPR Quant Ranking